...emergency authorization to Eli Lilly's rheumatoid arthritis drug Olumiant, in combination with Gilead's Remdesivir, for the treatment of COVID-19. Lilly in September released trial data that showed the combo was found to reduce recovery time for hospitalized COVID-19 patients. Under the pharmacy benefit, Olumiant holds preferred status under the pharmacy benefit for just 14% of covered lives, with utilization management restrictions. The drug is not covered for 25% of all insured lives.
SOURCE: MMIT Analytics, as of 11/23/20
No comments:
Post a Comment